Good Papers

CoMMa: Contribution-Aware Medical Multi-Agents for Decentralized Oncology Decision Support

CoMMa is a decentralized multi-agent oncology framework using partitioned data, specialized fine-tuning, and deterministic contribution-aware aggregation to enable interpretable, privacy-preserving decision support across diverse clinical settings.

Yichen WU, Yujin Oh, Sangjoon Park, Kailong Fan, Yuhan Liu, Zhiyi Shi, Sekeun Kim, Dania Daye, Hana Farzaneh, Wei Liu, Xiang Li, Raul N Uppot, Quanzheng Li

Published 2026Atlanta Poster Session 4 · Thu, Dec 10, 4:30 PM–7:30 PM local time · Hall C1arXiv ↗OpenReview ↗

80%
OverallMust read
?
OverallMust readVote to see the scoreThe exact score shows once you've voted, so every vote is your own call. The first half of each home page shelf shows its scores.
Readers
–

Only vote on papers you've read. Sign in with GitHub to vote.

AI panel12/20reviewers recommend it
lenient 5/5
medium 7/10
strict 0/5
AI panel?Vote to see what the 20 AI reviewers said

Abstract

Recent multi-agent frameworks have shown promise for oncology decision support, yet most assume centralized data access and rely on prompt-based assignment, limiting their applicability in privacy-sensitive clinical settings. We propose Contribution-Aware Medical Multi-Agents (CoMMa), a decentralized LLM-agent framework where specialists operate on partitioned clinical data streams. Unlike prior approaches that share inputs across agents, CoMMa enforces data decentralization to include stronger role specialization and further enhances this via agent-specific finetuning. To enable reliable and interpretable coordination, we introduce a contribution-aware aggregation mechanism that replaces stochastic, narrative-based reasoning with deterministic embedding projections to approximate each agent's marginal utility. This yields explicit credit assignment over agents, providing a stable and interpretable decision pathway aligned with clinical requirements. We evaluate CoMMa on multiple oncology benchmarks, including real-world multidisciplinary tumor board datasets from large academic hospitals in North America and East Asia, as well as public datasets, demonstrating strong performance and generalization across heterogeneous clinical settings.